"Rising HIV Drug Resistance to Dolutegravir Revealed in New Report"
The World Health Organization's latest HIV Drug Resistance Report highlights both positive and concerning trends in HIV treatment. While dolutegravir-containing therapy has shown high levels of viral load suppression, there is an increase in HIV drug resistance to dolutegravir, exceeding levels observed in clinical trials. The report emphasizes the need for standardized surveillance of HIV drug resistance and recommends actions to optimize the quality of HIV care delivery, including routine monitoring of quality-of-care indicators and addressing suboptimal performance. Additionally, cases of resistance to integrase-strand transfer inhibitors after exposure to cabotegravir have been documented, underscoring the importance of surveillance in the rollout of new HIV prevention options.